Arcus Biosciences, Inc. — Director's Dealing 2023

Jun 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arcus Biosciences, Inc. (RCUS)
CIK: 0001724521
Period of Report: 2023-06-15

Reporting Person: Lambert Nicole (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-15	Common Stock	A	6800	$0.00	Acquired	15600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-15	Stock Option (Right to Buy)	$19.60	A	19500	Acquired	2033-06-14	Common Stock (19500)	Direct

Footnotes

F1: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

F2: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.